Invex \u7684\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c<\/a>\u5c06\u62db\u52df\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u63a5\u53d7\u6bcf\u5468\u4e00\u6b21\u7684 Presendin \u6216\u5b89\u6170\u5242\u76ae\u4e0b\u6ce8\u5c04\uff0c\u4ee5\u8bc4\u4f30\u4ece\u57fa\u7ebf\u523024 \u5468\u7684\u9885\u5185\u538b\u5e73\u5747\u5dee\u5f02\u3002<\/p>\n\u8bd5\u9a8c\u7684\u6b21\u8981\u7ec8\u70b9\u5c06\u8bc4\u4f30\u4e24\u7ec4\u5728\u540c\u4e00\u65f6\u671f\u5185\u89c6\u529b\u548c\u6bcf\u6708\u5934\u75db\u5929\u6570\u7684\u5dee\u5f02\u3002<\/p>\n
\u6f14\u8bb2\u548c\u540c\u884c\u8bc4\u5ba1<\/h2>\n
Invex \u4ee3\u8868\u4e8e 2 \u6708\u5728\u5fb7\u514b\u8428\u65af\u5dde\u53c2\u52a0\u4e86\u7b2c 48 \u5c4aNorth American Neuro-Ophthalmology Society (NANOS) \u5e74\u4f1a\uff0c\u4ed6\u4eec\u8868\u793a\uff0c\u4ed6\u4eec\u5bf9\u795e\u7ecf\u773c\u79d1\u5b66\u754c\u5bf9\u7b2c\u4e8c\u9636\u6bb5\u538b\u529b\u8bd5\u9a8c\u7ed3\u679c\u7684\u201c\u5174\u8da3\u548c\u53c2\u4e0e\u611f\u5230\u9ad8\u5174\u201d\uff0c\u4ee5\u53caInvex \u7684 III \u671f IIH EVOLVE \u4e34\u5e8a\u8bd5\u9a8c\u8ba1\u5212\u3002<\/p>\n
\u8be5\u516c\u53f8\u5c06\u4e8e 6 \u6708\u5728\u82f1\u56fdBirmingham\u4e3e\u884c\u7684European Neuro-Ophthalmology Society (EUNOS) \u4f1a\u8bae\u4e0a\u8fdb\u884c\u8fdb\u4e00\u6b65\u7684\u4ecb\u7ecd\u3002<\/p>\n
\u5f3a\u5927\u7684\u8d22\u52a1\u72b6\u51b5<\/h2>\n
Invex \u4e00\u76f4\u4fdd\u6301\u5f3a\u52b2\u7684\u8d22\u52a1\u72b6\u51b5\uff0c\u622a\u81f3 3 \u6708\u5b63\u5ea6\u672b\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a 3040 \u4e07\u6fb3\u5143\u3002<\/p>\n
100 \u4e07\u6fb3\u5143\u7684\u73b0\u91d1\u6d41\u51fa\u5305\u62ec\u4e0e\u7814\u53d1\u3001\u7ba1\u7406\u548c\u516c\u53f8\u6210\u672c\u76f8\u5173\u7684\u8fd0\u8425\u652f\u51fa\u3002<\/p>\n
Invex \u9884\u6d4b\u672a\u6765\u4ea7\u54c1\u5236\u9020\u548c\u8fd0\u8425\u6210\u672c\u5c06\u4e0a\u5347\uff0c\u968f\u7740\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u7684\u589e\u52a0\u548c\u60a3\u8005\u62db\u52df\u7684\u589e\u52a0\uff0c\u9884\u8ba1\u5728\u968f\u540e\u7684\u65f6\u671f\u4f1a\u589e\u52a0\u8d2d\u4e70\u836f\u54c1\u3002<\/p>\n
\u8be5\u516c\u53f8\u5df2\u5ba3\u5e03\uff0c\u5b83\u5df2\u83b7\u5f97\u5168\u90e8\u8d44\u91d1\uff0c\u53ef\u4ece\u5f53\u524d\u7684\u73b0\u91d1\u50a8\u5907\u4e2d\u5b8c\u6210\u5176\u5728\u6b27\u6d32\u3001\u82f1\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u7684 Presendin \u6ce8\u518c\u8bd5\u9a8c\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002 \u8fd9\u5bb6\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u4eca\u5929\u63d0\u4f9b\u4e86\u5176 3 \u6708\u5b63\u5ea6\u6d3b\u52a8\u7684\u6700\u65b0\u4fe1\u606f\uff0c\u62a5\u544a\u4e86\u4e0e\u7b2c\u4e09\u65b9\u4f9b\u5e94\u5546\u7684\u8bb8\u591a\u5173\u952e\u670d\u52a1\u5408\u540c\u7684\u5b8c\u6210\u60c5\u51b5\u3002\u9664\u4e86\u836f\u54c1\u8fdb\u53e3\u3001\u5305\u88c5\u3001\u6807\u7b7e\u548c\u5206\u9500\u516c\u53f8\u4e4b\u5916\uff0c\u8fd9\u4e9b\u4f9b\u5e94\u5546\u8fd8\u5305\u62ec\u4e00\u5bb6\u9886\u5148\u7684\u5408\u540c\u7814\u7a76\u673a\u6784\u3002 Invex \u8fd8\u4e00\u76f4\u4e0e\u5176\u5236\u9020\u5408\u4f5c\u4f19\u4f34 Peptron \u548c\u987e\u95ee\u5bc6\u5207\u5408\u4f5c\uff0c\u4ee5\u5b8c\u6210\u5fc5\u8981\u7684\u6280\u672f\u5236\u9020\u548c\u63a7\u5236\u6587\u4ef6\uff0c\u540c\u65f6\u5168\u9762\u5ba1\u67e5\u5176\u836f\u7269\u914d\u65b9\u7684\u975e\u4e34\u5e8a\u548c\u4e34\u5e8a\u6570\u636e\uff0c\u4e3a\u8ba1\u5212\u5728\u82f1\u56fd\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u505a\u51c6\u5907\uff0c\u6b27\u6d32\u548c\u7f8e\u56fd\u5728\u516d\u6708\u5b63\u5ea6\u3002 Invex \u8fd8\u4e3a\u5176 IIH EVOLVE \u8bd5\u9a8c\u786e\u5b9a\u4e86 40 \u591a\u4e2a\u6f5c\u5728\u4e34\u5e8a\u5730\u70b9\uff0c\u76ee\u6807\u662f\u5728\u7f8e\u56fd\u3001\u6b27\u6d32\u3001\u82f1\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u3001\u65b0\u897f\u5170\u548c\u4ee5\u8272\u5217\u5f00\u8bbe\u7ea6 37 \u4e2a\u8fd9\u4e9b\u5730\u70b9\u3002 IIH \u662f\u4e00\u79cd\u795e\u7ecf\u7cfb\u7edf\u75be\u75c5\uff0c\u5176\u7279\u70b9\u662f\u9885\u5185\u538b\u4e25\u91cd\u5347\u9ad8\uff0c\u5bfc\u81f4\u65e0\u6cd5\u8fdb\u884c\u65e5\u5e38\u5934\u75db\uff0c\u5e76\u4e14\u4f1a\u538b\u8feb\u89c6\u795e\u7ecf\u3002\u7814\u7a76\u8868\u660e\uff0c\u5728\u8fc7\u53bb\u5341\u5e74\u4e2d\uff0c\u8be5\u75c5\u7684\u53d1\u75c5\u7387\u589e\u52a0\u4e86 350% \u4ee5\u4e0a\u3002 Invex \u7684\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u5c06\u62db\u52df\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u63a5\u53d7\u6bcf\u5468\u4e00\u6b21\u7684 Presendin \u6216\u5b89\u6170\u5242\u76ae\u4e0b\u6ce8\u5c04\uff0c\u4ee5\u8bc4\u4f30\u4ece\u57fa\u7ebf\u523024 \u5468\u7684\u9885\u5185\u538b\u5e73\u5747\u5dee\u5f02\u3002 \u8bd5\u9a8c\u7684\u6b21\u8981\u7ec8\u70b9\u5c06\u8bc4\u4f30\u4e24\u7ec4\u5728\u540c\u4e00\u65f6\u671f\u5185\u89c6\u529b\u548c\u6bcf\u6708\u5934\u75db\u5929\u6570\u7684\u5dee\u5f02\u3002 \u6f14\u8bb2\u548c\u540c\u884c\u8bc4\u5ba1 Invex \u4ee3\u8868\u4e8e 2 \u6708\u5728\u5fb7\u514b\u8428\u65af\u5dde\u53c2\u52a0\u4e86\u7b2c 48 \u5c4aNorth American Neuro-Ophthalmology Society (NANOS) \u5e74\u4f1a\uff0c\u4ed6\u4eec\u8868\u793a\uff0c\u4ed6\u4eec\u5bf9\u795e\u7ecf\u773c\u79d1\u5b66\u754c\u5bf9\u7b2c\u4e8c\u9636\u6bb5\u538b\u529b\u8bd5\u9a8c\u7ed3\u679c\u7684\u201c\u5174\u8da3\u548c\u53c2\u4e0e\u611f\u5230\u9ad8\u5174\u201d\uff0c\u4ee5\u53caInvex \u7684 III \u671f… Continue reading Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907<\/span><\/a><\/p>\n","protected":false},"author":5,"featured_media":10595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\nInvex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907<\/title>\n<meta name=\"description\" content=\"Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907\" \/>\n<meta property=\"og:description\" content=\"Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-19T05:28:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-idiopathic-intracranial-hypertension-IIH-phase-3-drug.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/\",\"name\":\"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-04-19T05:28:56+00:00\",\"dateModified\":\"2023-08-29T18:01:35+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907","description":"Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907","og_description":"Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/","og_site_name":"smallcapsCN","article_published_time":"2022-04-19T05:28:56+00:00","article_modified_time":"2023-08-29T18:01:35+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-idiopathic-intracranial-hypertension-IIH-phase-3-drug.jpg","type":"image\/jpeg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/","name":"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-04-19T05:28:56+00:00","dateModified":"2023-08-29T18:01:35+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"Invex Therapeutics (ASX: IXC) \u6b63\u5728\u7ee7\u7eed\u63a8\u8fdb\u5176\u5168\u7403 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u542f\u52a8\u51c6\u5907\u5de5\u4f5c\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u786e\u5b9a\u5176\u836f\u7269 Presendin \u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-continues-preparation-iih-evolve-phase-three-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u5728 IIH EVOLVE \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e4b\u524d\u7ee7\u7eed\u51c6\u5907"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4995"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4995"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4995\/revisions"}],"predecessor-version":[{"id":14874,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4995\/revisions\/14874"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/10595"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}